GlassScriptPhysician profile
Anne Growney
NPI 1457897282
$2,120.66
in general payments reported to CMS, 2019-2025
21 companies · $857 in 2025
The $857 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.55 · 2023: $395 · 2024: $854 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,037 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,037.12 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $410.26 | 2023-2025 | Verquvo, Belsomra, Capvaxive |
| Jazz Pharmaceuticals INC. | $269.56 | 2023-2025 | |
| Harmony Biosciences LLC | $257.50 | 2023-2025 | Wakix |
| Bayer Healthcare Pharmaceuticals INC. | $205.13 | 2023-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $161.57 | 2023-2025 | Lumryz |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $158.33 | 2023-2025 | Lifevest |
| Axsome Therapeutics, INC. | $136.77 | 2023-2025 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $83.27 | 2023-2024 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $67.55 | 2024-2025 | Camzyos, Eliquis |
| Lilly USA, LLC | $63.45 | 2025 | Zepbound, Mounjaro |
| Edwards Lifesciences Corporation | $51.25 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Idorsia Pharmaceuticals US INC | $46.31 | 2023-2024 | Quviviq |
| Novo Nordisk INC | $42.78 | 2024 | Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $37.62 | 2024 | |
| Medtronic, INC. | $31.13 | 2025 | Linq II |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicomp INC | $20.46 | 2024 | Telepatch Cardiac Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.13 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $16.37 | 2024 | Brilinta |
| Janssen Pharmaceuticals, INC | $15.18 | 2024 | Xarelto |
| Abbott Laboratories | $14.55 | 2022 | |
| Glaxosmithkline, LLC. | $14.49 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Growney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.